CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) ...

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

VALBY, Denmark, April 4, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin, in addition ...

Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, ...

INTERCEPT-AD Biomarker Results: Early effect of sabirnetug treatment on synaptic biomarkers in Alzheimer's disease (AAN Poster 3-003 in Neighborhood 3) This study was conducted to examine early ...

Dr Pavan Bhargava shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights into how new research in RRMS affects his patients.

Eisai Inc. announced today that the company will present the latest findings from its robust neurology portfolio, including data on real-world experience and continued maintenance dosing with our dual ...

at the American Academy of Neurology (AAN) Annual Meeting, taking place April 5-9, 2025, in San Diego, California. Ulviprubart is a first-in-class monoclonal antibody targeting killer cell lectin ...